Glycoprotein Glycan Modification Method
Summary
Amgen Inc. has filed patent application US20260110013A1 covering a method for manipulating the fucosylated glycan content on recombinant proteins. The application, filed on October 22, 2025 (Application No. 19365891), was published on April 23, 2026. Inventors Daniel R. Leiske and Michael T. Trentalange are credited with the invention, which has implications for biopharmaceutical development and glycoprotein-based therapeutic manufacturing.
“The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
This document publishes a new patent application by Amgen Inc. for a method of modifying glycoprotein glycan composition. The application covers techniques for manipulating fucosylated glycan levels on recombinant proteins, with CPC classifications spanning C07K (peptides), C12P (fermentation), and A61K (preparations for medical use).
Biopharmaceutical companies engaged in recombinant protein therapeutic development should monitor this application for potential freedom-to-operate considerations, particularly in glycoengineering applications. The named inventors' approach to glycan manipulation may be relevant to biosimilar development and antibody-dependent cellular cytotoxicity (ADCC) enhancement strategies.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN
Application US20260110013A1 Kind: A1 Apr 23, 2026
Assignee
AMGEN INC.
Inventors
Daniel R. LEISKE, Michael T. TRENTALANGE
Abstract
The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.
CPC Classifications
C12P 21/005 C07K 16/241 C07K 16/242 A61K 38/00 C07K 2317/41 C07K 2317/732 C07K 2317/734
Filing Date
2025-10-22
Application No.
19365891
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.